Abstract
Long-term management for leukemia is challenging due to the painful and invasive procedure of bone marrow (BM) biopsy. At present, non-invasive liquid (blood) biopsy is not utilized for leukemia, due to lower counts of leukemia blast cells in the blood. Here, we described a robust system for the simultaneous detection and enrichment of rare blast cells. Enrichment of blast cells was achieved from blood with a one-step microfluidic blast cell biochip (BCB) sorting system, without specific targeting of proteins by antibodies. Non-target cells encountered a differential net force as compared to stiffer blast cells and were removed. The efficiency of the BCB promotes high detection sensitivity (1 in 106 cells) even from patients with minimal residual disease. The procedure was validated using actual blast cells from patients with various types of leukemia. Outcomes were compared to current evaluation standards, such as flow cytometry, using BM aspirates. Blast cell detection efficiency was higher in 55.6% of the patients using the BCB as compared to flow cytometry, despite the lower concentrations of blast cells in liquid biopsy. These studies promote early-stage detection and routine monitoring for minimal residual disease in patients.
Highlights
Bone marrow aspirate (BMA) is a complex mixture of aspirated bone marrow (BM) cells, small tissue fragments, and peripheral blood
We have previously demonstrated the use of inertial microfluidics for sorting circulating tumor cells from peripheral blood of patients with solid tumors,[7,8] as well as infected malaria blood cells with relevance in disease detection.[9]
Design and fabrication of the blast cell biochip (BCB) We designed a microfluidic biochip for the detection of rare in actin filament release as well as its polymerization, and, an increase in cell stiffness
Summary
Bone marrow aspirate (BMA) is a complex mixture of aspirated BM cells, small tissue fragments, and peripheral blood. The gold standard is BM biopsy,[3] a procedure that is undesirable for several reasons: (1) high costs, (2) complexity of the surgical procedure, (3) discomfort from the invasive procedure, and (4) increased risk of mortality. Due to these factors, monitoring mutations or blast cell levels from BM biopsies is a tedious process as these procedures must be carried out on a routine basis. Clinicians are keen to introduce rapid, less invasive, and efficient screens for leukemia by employing the use of microfluidic-based assays, which is operated with minimal reagents and samples.[4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
